CN106459225A - O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 - Google Patents

O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 Download PDF

Info

Publication number
CN106459225A
CN106459225A CN201580023307.6A CN201580023307A CN106459225A CN 106459225 A CN106459225 A CN 106459225A CN 201580023307 A CN201580023307 A CN 201580023307A CN 106459225 A CN106459225 A CN 106459225A
Authority
CN
China
Prior art keywords
hpga
oac
pharmaceutically acceptable
acceptable salt
acetylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580023307.6A
Other languages
English (en)
Chinese (zh)
Inventor
Y.倪
M.斯普林格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomedicine
Original Assignee
Nanomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanomedicine filed Critical Nanomedicine
Publication of CN106459225A publication Critical patent/CN106459225A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201580023307.6A 2014-05-08 2015-05-08 O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 Pending CN106459225A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990493P 2014-05-08 2014-05-08
US61/990,493 2014-05-08
PCT/US2015/029979 WO2015172077A1 (fr) 2014-05-08 2015-05-08 Acides polygalacturoniques o-acétylés de haut poids moléculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi

Publications (1)

Publication Number Publication Date
CN106459225A true CN106459225A (zh) 2017-02-22

Family

ID=53190060

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580023307.6A Pending CN106459225A (zh) 2014-05-08 2015-05-08 O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途

Country Status (6)

Country Link
EP (1) EP3140324A1 (fr)
JP (1) JP2017514961A (fr)
CN (1) CN106459225A (fr)
AU (1) AU2015255693A1 (fr)
CA (1) CA2946900A1 (fr)
WO (1) WO2015172077A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691986B2 (en) * 1998-05-13 2010-04-06 Nanotherapeutics, Inc. High molecular weight, low methoxyl pectins, and their production and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691986B2 (en) * 1998-05-13 2010-04-06 Nanotherapeutics, Inc. High molecular weight, low methoxyl pectins, and their production and uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOGUSLAW SZEWCZYK等: ""Immunochemical Properties of Vi Antigen from Salmonella typhi Ty2: Presence of Two Antigenic Determinants"", 《INFECTION AND IMMUNITY》 *
RICHARD G. SCHWEIGER: ""Acetyl Pectates and Their Reactivity with Polyvalent Metal Ions"", 《J. ORG. CHEM.》 *
SHOUSUN C. SZU等: ""Synthesis and Some Immunologic Properties of an O-Acetyl Pectin [Poly(l1->4)-C-D-GalpA]-Protein Conjugate as a Vaccine for Typhoid Fever"", 《INFECTION AND IMMUNITY》 *

Also Published As

Publication number Publication date
JP2017514961A (ja) 2017-06-08
CA2946900A1 (fr) 2015-11-12
AU2015255693A1 (en) 2016-11-03
WO2015172077A1 (fr) 2015-11-12
WO2015172077A8 (fr) 2016-01-28
EP3140324A1 (fr) 2017-03-15

Similar Documents

Publication Publication Date Title
Micoli et al. Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi
Gupta et al. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin
Haughney et al. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles
RU2684615C2 (ru) Бактериальная вакцина и способы ее получения
CN107073092A (zh) 基于鞭毛蛋白的剂及包括有效接种的用途
Hitri et al. O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes
Zhang et al. Synthetic glycans and glycomimetics: a promising alternative to natural polysaccharides
JP6166533B2 (ja) ピロリ菌リポ多糖類の外殻エピトープ
KR20120104178A (ko) 면역원성이 개선된 단백질 매트릭스 백신
Szu et al. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine
CN110302375A (zh) 一种糖缀合物及其用途
An et al. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine
Abo et al. Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy
Szu et al. Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis, and Escherichia coli O157: H7
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
CN106459225A (zh) O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途
An et al. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever
Ni et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever
WO2014195880A1 (fr) Antigène bactérien immunogène isolé et son utilisation pour la prévention et le traitement d'infections causées par des bactéries à gram négatif
EA030920B1 (ru) Экзополисахарид бактерии shigella sonnei, способ его получения и включающие его вакцина и фармацевтическая композиция
Ghaderinia et al. Immunogenic Evaluation of MPEG-PCL & PLGA Nanoparticles Containing Klebsiella pneumoniae K2O1 Capsular Antigen in Pulmonary Infection Model of Mice
Jones Chemistry Manufacturing, Control, and Licensure for Carbohydrate-Based Vaccines
De Benedetto Characterization of polysaccharide-based vaccines against invasive nontyphoidal Salmonella disease (iNTS)
Kumar et al. Typhoid Vaccines
US20210401960A1 (en) Multivalent glycoconjugates immunogenic compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222